Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

18,893 total articles

Bread Financial Announces Launch of an Offering of Depositary Shares Representing Interests in Its Series B Preferred Stock

Bread Financial Announces Launch of an Offering of Depositary Shares Representing Interests in Its Series B Preferred Stock

Bread Financial Holdings, Inc. announced the launch of an underwritten public offering of depositary shares representing interests in its Series B Preferred Stock. The company plans to use the proceeds for general corporate purposes such as lending to its subsidiary bank and share repurchases. The offering is subject to market conditions and will b…

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD

Clearmind Medicine Inc. has filed a European patent application for innovative psychedelic compounds aimed at treating PTSD and other mental health disorders, strengthening its intellectual property position in Europe. This move aligns with a new U.S. executive order promoting the advancement of psychedelic-based therapies, highlighting significant…

Clene Announces $7 Million Underwritten Offering of Common Stock

Clene Announces $7 Million Underwritten Offering of Common Stock

Clene Inc., a clinical-stage biopharmaceutical company, announced a $7 million underwritten offering of common stock priced at $7.00 per share. The proceeds are intended to support general corporate purposes including the preparation and filing of a New Drug Application for its lead drug candidate CNM-Au8®, ongoing clinical trials, manufacturing ex…

Victoria’s Secret & Co. Board Comments on BBRC’s Distracting Proxy Contest; Underscores Significant Outperformance and Board’s Commitment to Acting in the Best Interest of Shareholders

Victoria’s Secret & Co. Board Comments on BBRC’s Distracting Proxy Contest; Underscores Significant Outperformance and Board’s Commitment to Acting in the Best Interest of Shareholders

Victoria's Secret & Co. Board addresses BBRC International Pte Limited's proxy contest led by Brett Blundy after the Board declined his appointment as a director, citing reputational and governance risks. The Board emphasizes the Company’s strong performance under CEO Hillary Super, with significant shareholder returns and commitment to executing t…

Birchtech Announces Appointment of Respected Finance Executive Michael Mioska as Chief Financial Officer

Birchtech Announces Appointment of Respected Finance Executive Michael Mioska as Chief Financial Officer

Birchtech Corp., a leader in specialty activated carbon technologies for air and water purification, has appointed Michael Mioska as its new Chief Financial Officer. Mioska brings over 20 years of finance and audit experience, including recent consulting work with Birchtech. The company expects his leadership will facilitate scaling their platforms…

TRUGOLF LINKS REGIONAL DEVELOPER SIGNS LEASE FOR SECOND LOCATION

TRUGOLF LINKS REGIONAL DEVELOPER SIGNS LEASE FOR SECOND LOCATION

TruGolf, a Nasdaq-listed company specializing in high-tech golf simulators, has signed a lease for a second flagship TruGolf Links Center location in Farmingdale, New York. This new 6,120 square foot facility will offer premium indoor golf simulators, an upscale restaurant with a full bar, and a multi-sport arcade, aiming to deliver an enhanced 'ea…

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

Fate Therapeutics announced FT819, its off-the-shelf CAR T-cell therapy candidate for moderate-to-severe systemic lupus erythematosus (SLE), has been selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program. Coupled with the existing Regenerative Medicine Advanced Therapy (RMAT) designation, this …

Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites

Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites

Microbot Medical Inc. announced strong commercial adoption of its LIBERTY Endovascular Robotic System, including by sites involved in the ACCESS-PVI pivotal clinical trial. The company is experiencing increased interest following its full market release and is expanding its global presence, highlighted by participation in the upcoming GEST Conferen…

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics CEO Issues Letter to Shareholders

FibroBiologics, Inc., a clinical-stage biotechnology company, announced the initiation of its clinical trial for CYWC628, an investigational fibroblast-based therapy aimed at treating diabetic foot ulcers (DFUs). The company highlighted the importance of this milestone as it transitions from development to clinical execution. It plans to begin pati…

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB Biotherapeutics, Inc. will release its first quarter 2026 financial results on May 12, 2026, followed by a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates. The company is a clinical-stage biopharmaceutical firm focused on developing fully human immunoglobulin therapeutics for autoimmune diseases, wi…

BGIN BLOCKCHAIN LIMITED Reveals PortableBTC at Bitcoin 2026

BGIN BLOCKCHAIN LIMITED Reveals PortableBTC at Bitcoin 2026

BGIN BLOCKCHAIN LIMITED revealed its PortableBTC commemorative prototype miner at the Bitcoin 2026 conference, signaling the company's move into Bitcoin mining hardware development and consumer-oriented mining products under its "Crypto for All" vision. The prototype, powered by the company's BT1 ASIC chip, represents a milestone in BGIN's ASIC des…

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026

IMUNON, Inc., a clinical-stage biotech developing DNA-mediated immunotherapies, announced its Q1 2026 financial results and business update conference call set for May 12, 2026. The company will provide updates on IMNN-001, its lead DNA-based interleukin-12 immunotherapy in Phase 3 trials for advanced ovarian cancer, and report progress on its clin…

Chanson International Holding Announces 100 for 1 Share Consolidation

Chanson International Holding Announces 100 for 1 Share Consolidation

Chanson International Holding, a China and US-based bakery and beverage products provider listed on Nasdaq under the ticker CHSN, announced a 100-for-1 share consolidation effective May 7, 2026. The consolidation will reduce the total shares outstanding, increase the par value per share, and maintain the current trading symbol under a new CUSIP. Th…

Foremost Clean Energy Advances CLK Uranium Property With Results of MobileMT and Ambient Noise Tomography Surveys Following up Historic High-Grade Showing

Foremost Clean Energy Advances CLK Uranium Property With Results of MobileMT and Ambient Noise Tomography Surveys Following up Historic High-Grade Showing

Foremost Clean Energy Ltd. announced results from its 2025 helicopter-borne MobileMT electromagnetic survey and ambient noise tomography survey at its CLK Uranium Property in Saskatchewan's Athabasca Basin. The surveys identified complex conductive anomalies and structural features associated with high-grade uranium mineralization, supporting refin…

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

Palisade Bio announced additional Phase 1a/b data for PALI-2108, a once-daily oral PDE4 inhibitor prodrug selectively activated in the ileum and colon, demonstrating sustained target engagement above IC90, colon-selective pathway modulation, and strong clinical, histologic, and biomarker improvements in ulcerative colitis patients. This supports co…

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

Profusa, Inc. has announced a board-led process to evaluate strategic growth alternatives, including partnerships, mergers, or asset transactions, aiming to enhance scale and shareholder value. Concurrently, the company is focusing resources on advancing the Lumee Oxygen platform toward European CE Mark certification and expanding revenue through i…